**Utility of 18F-Flurpiridaz PET Relative Flow Reserve in Differentiating Obstructive from Nonobstructive Coronary Artery Disease**

**Short Title**: Utility of PET RFR in CAD

Diana M. Lopez, MD,[a] Dan Huck, MD, MPH,[a] Sanjay Divakaran, MD, MPH, Jenifer M. Brown, MD,[a] Brittany Weber, MD, PhD,[a] Mark Lemley, BS,[b] Valerie Builoff, BS,[b] Aakash Shanbhag, PhD,[b] Zhou Lan, PhD,[c,d] Christopher Buckley, PhD,[e] Mouaz H. Al-Mallah, MD,[f] Sharmila Dorbala, MD,[a] Ron Blankstein, MD,[a] Piotr Slomka, PhD,[b,*] Marcelo F. Di Carli, MD.[a,*]

From the [a]Cardiovascular Imaging Program, Departments of Medicine and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; [b]Department of Medicine Cedars-Sinai, Los Angeles, California, USA; [c]Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; [d]Center for Clinical Investigation, Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; [e]GE Healthcare, Pharmaceutical Diagnostics, Buckinghamshire, UK; [f]Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA.

*Drs. Di Carli and Slomka contributed equally to this work and serve as joint senior authors.

The first author had full access to all the data in the study and takes responsibility for its integrity and the data analysis.

**Address for Correspondence:**
Dr. Diana M. Lopez
Brigham & Women's Hospital
75 Francis Street, PBB1
Boston, MA 02115
Tel: 1 617-732-6291
Fax: 1 617-582-6056
E-mail: dlopez@bwh.harvard.edu
@DMLopez5

**Word Count**: 5994

## Abstract

**Background:** Absolute quantification of myocardial blood flow (MBF) on PET perfusion imaging improves the identification of coronary artery disease (CAD). However, distinguishing MBF impairment due to obstructive CAD from nonobstructive CAD remains challenging. We aimed to evaluate the incremental diagnostic value of PET-derived relative flow reserve (RFR) in the diagnosis of obstructive CAD.

**Methods:** This is a post hoc analysis of the multicenter phase-III trial of $^{18}$F-flurpiridaz PET (NCT01347710). Patients with available MBF quantification were included. Reduced stress MBF (sMBF) was defined as sMBF below the median (2.2 mL/min/g). Obstructive CAD on quantitative invasive coronary angiography (ICA) was defined as $\geq$70% stenosis. RFR was calculated as a ratio of the minimal segment sMBF over the highest reference vascular territory sMBF. RFR performance for predicting obstructive CAD was evaluated through Receiver Operating Characteristic (ROC) analysis and the net reclassification index (NRI) of multivariable regression models.

**Results**: The study included 231 patients (71% male; 56% with established CAD) drawn from the original cohort of 755 trial participants. No patients had three-vessel CAD. In a per vessel-based analysis, 84% of vessels with reduced sMBF had no obstructive CAD on ICA. RFR was significantly lower for vessels with obstructive CAD (0.55 vs 0.80, p<0.0001). In vessels with reduced sMBF, RFR was independently associated with obstructive CAD even after accounting for sTPD and MFR (OR 3.08, 95% CI: 1.49–6.38; p = 0.002). While the addition of RFR did not significantly improve discrimination (AUC 0.806 vs. 0.822, p = 0.11), it significantly improved reclassification of vessels with and without obstructive CAD (NRI: 0.93, p < 0.0001).

**Conclusions:** RFR provides complementary diagnostic information beyond existing PET parameters and may help refine the diagnosis of obstructive CAD in patients with reduced flows.

**Non-standard Abbreviations and Acronyms**
CMD = coronary microvascular disease
sMBF = stress myocardial blood flow
MFR = myocardial flow reserve
RFR = relative flow reserve
sTPD = stress total perfusion deficit

**Clinical Perspective**

A major diagnostic dilemma in cardiac PET/CT perfusion imaging is determining whether reductions in stress myocardial blood flow and/or myocardial flow reserve are caused by obstructive or nonobstructive coronary artery disease (CAD), leading to uncertainty about whether invasive angiography is needed. Our study demonstrates that incorporating PET-derived relative flow reserve (RFR) adds meaningful diagnostic information beyond existing PET perfusion and flow parameters. RFR does not substantially increase overall discrimination between obstructive and nonobstructive CAD, but it significantly improves reclassification of individual cases, indicating that RFR can help refine decision-making, particularly in borderline cases. These data suggest that selective integration of RFR with existing PET metrics could improve patient selection for invasive procedures and guide more targeted medical therapy for nonobstructive CAD. Future research is needed to confirm these findings across a broader patient population, including higher-risk cohorts and women, as well as with other PET radiotracers.

**Introduction**

A major diagnostic dilemma in cardiac PET/CT perfusion imaging is determining whether reductions in stress myocardial blood flow (sMBF) and/or myocardial flow reserve (MFR) are caused by obstructive or nonobstructive coronary artery disease (CAD) – a distinction that has significant implications for additional testing, including referral to invasive coronary angiography (ICA). Cardiac PET/CT perfusion imaging integrates multiple physiologic imaging parameters, which improves the identification and risk stratification of coronary artery disease (CAD).[1,2] However, reductions in sMBF and MFR can occur in the absence of focal obstructive epicardial disease.[2-4] This is attributed to the presence of diffuse nonobstructive epicardial atherosclerosis and coronary microvascular disease, which are increasingly prevalent with the rise of cardiometabolic disease.[5-8] From a clinical perspective, the presence of regional or global reductions in sMBF and/or MFR in patients with normal or mildly abnormal myocardial perfusion creates uncertainty regarding the underlying cause of the flow abnormalities. Consequently, additional tools are needed to differentiate classic obstructive CAD from nonobstructive atherosclerosis.

Prior studies have investigated the diagnostic utility of the PET-derived relative flow reserve (RFR), a non-invasive measure that compares sMBF in a myocardial region of interest to a normal reference region, thereby calculating a flow ratio to understand whether the stenosis is hemodynamically significant.[9-13] Coronary flow and pressure are linearly related under maximal hyperemic conditions; thus, the RFR could function as a non-invasive surrogate of the fractional flow reserve measured using a pressure wire in the catheterization laboratory. Prior studies have shown that RFR, when used as a standalone metric, was not superior to sMBF or MFR for

detecting flow-limiting CAD.[9-11] However, the complementary role of RFR in distinguishing

PET myocardial flow abnormalities caused by angiographically obstructive CAD from those

associated with diffuse nonobstructive atherosclerosis remains unclear. Therefore, our objective

was to investigate the incremental value of RFR when integrated with existing quantitative PET

parameters in symptomatic patients who underwent Flurpiridaz PET and invasive angiography as

part of a blinded prospective phase III study.[14]

**Methods**

**Study Population**

Patients were drawn from the first Flurpiridaz myocardial perfusion PET phase III trial

(NCT01347710).[14] Briefly, participants were $\geq$18 years old and had to be referred for clinically

indicated ICA. Major exclusion criteria included acute coronary syndrome or percutaneous

coronary intervention within 6 months, stroke within 3 months, prior coronary artery bypass

graft surgery, symptomatic valvular disease, significant congenital heart defects, New York

Heart Association functional class III-IV heart failure, nonischemic cardiomyopathy, and history

of heart transplantation. Pre-test probability of CAD was assessed per the ACC/AHA guidelines

for exercise testing.[15] PET studies were performed within 60 days of ICA. Dynamic imaging for

absolute flow quantification was optional and performed at the discretion of the recruitment sites.

Institutional Review Board approval was obtained at each study site and written informed

consent was obtained from all the trial patients.

**Invasive Coronary Angiography**

ICA was performed in accordance with each site's clinical protocol. Images were evaluated by

the designated angiography core laboratory (Boston Clinical Research Institute, Boston, MA,

USA) for blinded quantitative percent diameter coronary stenosis measurements (QCAPlus,

Sanders Data Systems, Palo Alto, CA USA). For this post hoc study, obstructive CAD was

defined as ≥ 70% stenosis in the left anterior descending artery (LAD), left circumflex artery

(LCX), right coronary artery (RCA), or their major branches, and ≥ 50% stenosis in the left main

artery (LM). Obstructive CAD in the LM was categorized as 2-vessel CAD.

**Flurpiridaz Myocardial Perfusion PET/CT Imaging Protocol**

PET myocardial perfusion imaging (MPI) was performed as previously described.[14, 16] Briefly,

vasodilator stress was performed with regadenoson, adenosine, or dipyridamole in accordance

with each study site's protocol. Dynamic PET MPI acquisition at rest and at peak stress was

performed following intravenous bolus injections of ^{18}F-flurpiridaz at doses of 2.7 ± 0.2 mCi and

5.9 ± 0.3 mCi, respectively, with a minimum of a 30-minute interval between rest and stress

injections.

*Motion Correction:* Motion was corrected manually for each frame at stress and rest to align the

myocardial tracer uptake in each frame with myocardial contours, as previously reported.[17, 18]

For each frame in each dataset, the operators shifted the image in relation to the static LV

myocardial contours from the static image in the three principal axes (x: lateral to septal, y:

anterior to inferior, and z: apex to base). The magnitude of motion was then assessed across all

patients in the direction of each of the axes. The frequency of motion shift ≥ 5 mm was

calculated.

*Residual Activity Subtraction:* Residual activity correction (RAC) was applied to the stress

dynamic images to account for the bias introduced by the residual 18F-flurpiridaz activity from

the rest injection, as previously described.[17, 19]

**Relative Perfusion Image Analysis:** For semiquantitative perfusion analysis, static images were

created by summing the dynamic PET images after the initial 2 minutes. Perfusion images were

processed in batch mode with dedicated software (QPET, Cedars-Sinai Medical Center, Los

Angeles, CA).[20] The total perfusion deficit (TPD) at rest and stress was computed as previously

described for the entire left ventricle and each coronary vascular territory (LAD, LCX, RCA).[21]

Ischemic TPD was also calculated and defined as the difference between stress and rest TPD.

Abnormal stress total perfusion deficit (sTPD) was defined as $\geq$7%, a threshold previously found

to provide the optimal diagnostic operating point.[22]

**Quantification of Myocardial Blood Flow and Flow Reserve**

Myocardial blood flow and flow reserve maps were generated from the dynamic image series

with the QPET software using a 2-compartment kinetic model.[19] Quantitative MBF in each

coronary territory was estimated using the tracer uptake kinetics within the first 90 seconds post-

tracer injection. The spillover fraction from the blood pool to the myocardium plus the vascular

volume of distribution was approximated as 1.0 minus the recovery coefficient of the

corresponding myocardial sample. MBF was obtained by assuming a first-pass extraction

fraction of 0.94.[23] Myocardial flow reserve polar maps were computed by dividing the stress and

rest MBF in each polar map sample. Average MBF and MFR values were quantified for the

entire left ventricle, each coronary vascular territory (LAD, LCX, RCA), and for each of the 17

myocardial segments in accordance with AHA standardized segmentation model.[24] MBF

measurements were not adjusted for rate pressure product. Since the threshold for an abnormal

$^{18}$F-flurpiridaz sMBF has not been established in larger studies, we defined reduced per vessel

sMBF as values falling below the group median. Severely reduced sMBF was defined as < 1.5

ml/min/g.[25] Impaired MFR was defined as MFR <2.0.[26, 27]

**Relative Flow Reserve**

The relative flow reserve was calculated for each vessel by dividing the lowest segmental

sMBF[12] in each vessel territory by the average sMBF in the territory with the highest flow value,

which was considered the reference territory (Supplementary Figure 1). This approach is

consistent with previously published RFR methodology and allows for patient-specific

normalization based on the most preserved vascular territory.[9, 10, 12] The apical 17th segment was

excluded in the estimation of LAD RFR. The process was automated to determine the lowest

segmental and reference vascular flows without user selection and the reviewer assessing these

values was blinded to the presence or absence of obstructive CAD on ICA.

**Statistical Analysis**

Categorical variables are reported as frequencies with percentage and compared using chi-

squared test. Continuous variables are presented as mean ± standard deviation or median with

interquartile range (IQR), and compared using Wilcoxon rank-sum and Kruskal-Wallis tests, as

appropriate.

Per-vessel analyses were performed by clustering at the patient level to account for within-

patient correlation. Each patient contributed up to three matched PET and ICA measurements

(LAD, LCX, and RCA). Univariate receiver operating characteristic (ROC) analysis was

performed for each PET parameter and differences in area under the curve (AUC) were

compared using DeLong's test, with 95% confidence intervals (CI) estimated via clustered

bootstrapping. Predictive margins were plotted from a generalized estimating equations (GEE)

model with patient-level clustering. The optimal RFR threshold was selected with Youden's

index. To evaluate the incremental diagnostic value of RFR, multivariable logistic regression

models with GEE to account for clustering. Models included adjustment for age, sex, and BMI.

Interaction terms between the PET parameters were retained only if statistically significant. ROC

and continuous net reclassification index (NRI) further assessed model performance, with CI and

comparisons derived from clustered bootstrapping. All tests were 2-sided, and $p < 0.05$ was

considered statistically significant. Analyses were performed using Stata/BE 17.0 (Statacorp) and

R version 4.5.0 (R Foundation for Statistical Computing).

**Results**

**Study Population**

Absolute flow quantification was available for 275 of the 755 patients in the trial. Of these, 231

patients were included in this post hoc study after excluding studies with limited quality flow

data. Reasons for quality control failure included missing or corrupted dynamic images (n = 5),

unavailable heart rate and blood pressure at rest (n = 1), or abnormal left ventricular (LV) input

curves (n = 38), defined as flat curves, absent peaks, or multiple peaks. Patient characteristics are

summarized in **Table 1**. The mean age was 61.9 years (± 9.4), and the majority of the study

participants were white (78%), male (70%), had established CAD (56%) and a high burden of

cardiometabolic risk factors. Most patients were symptomatic (88%), with typical chest pain

being the most common reason for ICA referral (45%).

**PET and ICA Results**

The per-patient PET and ICA results are summarized in Table 1 and Supplementary Table 1. The

per-vessel PET and ICA results are summarized in **Table 2**.  Although there was a high burden

of symptoms and cardiometabolic risk factors, only 25.5% of patients (59 out of 231) had

obstructive CAD on ICA. The proportion of multi-vessel obstructive CAD was low, with less

than 10% of patients found to have 2-vessel obstructive CAD and no patients with 3-vessel

obstructive CAD. The median sMBF was 2.2 mL/min/g (IQR 1.7, 2.8) and median MFR was 2.9

(IQR 2.2, 3.7); these values were consistent at both the global and per-vessel levels. The burden

of angiographically obstructive CAD was low (73 of 693 vessels (10.5%)). Vessels with

obstructive CAD had a lower RFR when compared to nonobstructive vessels (0.55 vs 0.80, p

<0.0001).

**Obstructive CAD by PET Flow and Flow Reserve**

To investigate the relationship between per vessel sMBF and angiographic stenosis in this study

population, we examined the distribution of obstructive CAD by sMBF and MFR (**Figure 1**).

The majority of vessels with angiographically obstructive CAD had reduced sMBF (88%, p

<0.001). Of these, the largest proportion (53%) had concordantly reduced sMBF and MFR (p

<0.001). However, most vessels with reduced sMBF (82%, 282/346), including those with

concordantly reduced MFR (61%, 60/99), had no obstructive CAD on ICA.

**Integration of Flow and Perfusion Metrics**

Given that the clinical interpretation of stress PET MPI relies on both flow and perfusion metrics, we examined the distribution of obstructive CAD when stratifying vessels by both abnormal sMBF and abnormal sTPD (>7%) (**Figure 2**). In vessels with normal sMBF, an abnormal sTPD did not significantly differentiate vessels with and without obstructive CAD (p = 0.298), reflecting the low prevalence of obstructive disease (n=9 vessels) in this subgroup. In vessels with reduced sMBF, an abnormal sTPD was associated with a higher proportion of vessels with obstructive CAD compared to a normal sTPD (43% vs 8%, respectively, p <0.0001); however, notably more than half of the vessels with abnormal sTPD and reduced sMBF had nonobstructive CAD on ICA.

**RFR and Stenosis Severity**

We examined the distribution of RFR across increasing severities of epicardial coronary stenoses (**Figure 3A**). The mean and median RFR for all vessels were $0.77 \pm 0.19$ and 0.79 (IQR 0.66 – 0.90), respectively. An inverse relationship was observed between RFR and stenosis severity, with lower RFR values indicating more severe angiographic disease. While the RFR subtly decreased with mild and moderately stenosed vessels, it dropped significantly to median RFR of 0.55 (IQR 0.43 – 0.70) with severely stenotic lesions (p = 0.001). Importantly, RFR differences between obstructive vs nonobstructive vessels were evident across all three vascular territories (**Figure 3B**).

The per-vessel standalone discriminatory power of RFR and the other PET metrics is shown in

**Supplementary Figure 2**. The optimal RFR cutoff for the diagnosis of obstructive CAD was

0.64 with sensitivity and specific of 67% and 84% respectively. Furthermore, there was a

nonsignificant trend toward a higher probability of obstructive CAD with lower RFR values at a

given MBF or sTPD **(Supplementary Figure 3)**.

**Incremental Diagnostic Value of RFR**

To investigate the incremental value of RFR, multivariable logistic analysis was performed on

vessels with reduced sMBF (**Table 3**). Even after adjusting for clinical covariates, sTPD, and

MFR, RFR was independently associated with a threefold higher odds of obstructive CAD (OR

3.08, 95% CI 1.49–6.38, p=0.002). The addition of RFR improved discrimination between

obstructive and nonobstructive CAD when compared to using either sTPD alone (AUC 0.763 vs

0.794, p = 0.010; **Figure 4**) or to MFR alone (AUC 0.718 vs 0.801, p < 0.002; **Supplementary**

**Figure 4**). However, RFR did not significantly improve discrimination when added to both

sTPD and MFR (AUC 0.806 vs 0.822, p = 0.11; **Figure 4**). From a reclassification standpoint,

however, the addition of RFR yielded a significant improvement over both sTPD alone (NRI of

0.958, 95% CI: 0.710–1.206, p < 0.0001) and a combination of both sTPD and MFR (NRI of

0.927, 95% CI: 0.665–1.188, p < 0.0001) (**Table 4**).

**<u>Discussion</u>**

Accurate and reproducible MBF quantification is a key advantage of PET MPI over other cardiac

imaging modalities. These flow measurements improve detection of flow-limiting CAD and risk

stratification in all patient groups.[28-30] Nevertheless, the interpretation of reduced flows often

introduces diagnostic uncertainty as to whether they reflect underlying obstructive or

nonobstructive CAD. The integrated assessment of sMBF and MFR was previously shown to

identify differential risk for cardiac death.[31] Our study builds on this by showing that

concordantly reduced regional sMBF and MFR were associated with the highest prevalence of

obstructive CAD. Yet, 82% of vascular territories with reduced sMBF—and 61% of those with

concordantly impaired sMBF and MFR—had no obstructive CAD, highlighting the need for

additional metrics to refine diagnostic certainty in patients with impaired PET flow parameters.

Lower flow impairment thresholds have been proposed to improve specificity for detecting

obstructive CAD.[27] Still, in our study, most vascular territories with severely reduced sMBF

(<1.5 mL/min/g) did not have obstructive CAD on ICA. Abnormal perfusion (sTPD $\geq$7%)

improved the differentiation between obstructive and nonobstructive CAD, but more than half of

the vascular territories with abnormal sMBF and sTPD had nonobstructive CAD. These findings

highlight the limitations of existing PET metrics. This is especially relevant with high extraction

fraction tracers like ^{18}F-flurpiridaz, ^{13}N-ammonia, and ^{15}O-water—as these agents are more

sensitive flow limitations caused by moderate or diffuse disease—and emphasize the need for

additional strategies.

In this context, our study offers new insights into the application of ^{18}F-flurpiridaz PET-derived

RFR for the diagnosis of obstructive CAD. We found that RFR was strongly associated with

stenosis severity, with the lowest values in vessels with severe stenoses. Among vessels with

reduced sMBF, RFR was independently predictive of obstructive CAD, even after accounting for

perfusion and MFR (OR 3.08; p=0.002), suggesting that RFR provides distinct physiologic

information. RFR did not significantly improve global discriminatory performance (AUC 0.806

vs 0.822, p = 0.11), but it improved vessel-level classification beyond sMBF and MFR for both

obstructive and nonobstructive CAD cases. As such, RFR may be particularly useful for

clarifying diagnostic uncertainty in patients with intermediate findings on sTPD or MFR.

While ROC-based test assessment is often the go-to approach, the AUC or c statistic can be

relatively insensitive to incremental improvements in prediction, particularly when the baseline

test already demonstrates good discrimination. Cook[32] notes that even well-established predictors

of CVD may have only a marginal impact on the c statistic individually, especially if the new

metric is geared more toward refining individual risk prediction rather than overall

discrimination. Kerr et al.[33] similarly caution against relying solely on NRI-based assessment.

Guided by these principles, this study did not rely on a single metric but rather evaluated the

added value of RFR through multiple complementary approaches.

Past studies that evaluated the diagnostic utility of PET-derived RFR had mixed results.[9-13]

Stuijfzand et al.[9] reported that RFR was not superior to sMBF or MFR in diagnosing obstructive

CAD. Cho et al.[11] showed that RFR declined more prominently with focal stenosis and remained

relatively preserved in the setting of diffuse atherosclerosis compared to MFR, suggesting that

RFR provides complementary physiologic insights. These findings highlight the importance of

integrating multiple PET-derived parameters to comprehensively phenotype coronary

physiology.

The integration of RFR requires an understanding how this metric aligns with both anatomical

and hemodynamic assessments of stenosis severity. De Bruyne et al.[13] demonstrated that RFR

correlates better with invasive fractional flow reserve (FFR) than with percent diameter stenosis.

This may explain the wide RFR distribution in vessels with severe stenosis. Notably, this is not

unique to RFR. Severe stenosis on ICA can be associated with substantial variability in PET-

based sMBF and MFR,[25, 34, 35] as well as invasive FFR.[36, 37] Similarly, we observed that vessels

without obstructive CAD often had RFR values well below 1.0—paralleling the phenomenon in

which diffuse nonobstructive disease can also yield abnormal FFR values.[36-38] This physiologic-

anatomic discordance may have also impacted RFR's ability to improve the ROC-based

discrimination assessment, which essentially reflects how well a test separates two groups as

distinct populations.

**Limitations**

Our study has several limitations. Patients underwent routine clinically indicated ICAs and

invasive FFR was not available. However, anatomical stenosis remains the most common metric

for assessing lesion severity in clinical practice. MBF quantification was not performed in all

trial participants and patients who received PCI at the time of ICA were excluded from the trial,

potentially limiting generalizability. Raw ICA images were not available; so vessel assignment

was based on standard territory definitions, which may not reflect individual patient anatomy. No

patients had three-vessel obstructive CAD, so RFR's utility in this group remains unknown. The

cohort was mostly male, warranting further investigation of RFR performance in women.

Finally, these findings apply to 18F-flurpiridaz PET-derived RFR; further studies are needed to

assess RFR performance in other PET tracers like [82]Rb-rubidium, as its lower extraction fraction

may affect RFR performance and diagnostic thresholds.

**<u>Conclusions:</u>**

In patients with 1- to 2-vessel obstructive CAD, RFR is significantly reduced in vessels with

severe stenoses and provides incremental diagnostic value in differentiating obstructive and

nonobstructive CAD in vessels with reduced myocardial blood flow.

**Acknowledgements:**

This work was conducted with support from Harvard Catalyst | The Harvard Clinical and

Translational Science Center (National Center for Advancing Translational Sciences, National

Institutes of Health Award UL 1TR002541).

**Funding and Support**:
DMH is supported by an American Heart Association Career Development Award
[23CDA1037589]. SDV is supported by Boston Claude D. Pepper Older Americans
Independence Center [5P30AG031679–10] and an American Society of Nuclear
Cardiology/Institute for the Advancement of Nuclear Cardiology Research Fellowship Award.
JMB is supported by an American Heart Association Career Development Award [852429] and
NIH/National Heart Lung and Blood Institute K23 grant [K23HL159279]. BW is supported by
an American Heart Association Career Development Award [21CDA851511], NIH/National
Heart Lung and Blood Institute K23 grant [HL159276–01] and ASNC IANC Research Award.
PS is supported by an NIH/National Heart Lung and Blood Institute grant [R35HL161195] and
by an NIH/ National Institute of Biomedical Imaging and Bioengineering grant [R01EB03458].

448
449

**Author Disclosures:**
The authors declare the following financial interests/personal relationships which may be
considered as potential competing interests: Diana Lopez reports a relationship with New
Amsterdam that includes consulting or advisory. Sanjay Divakaran reports a relationship with
Kinevant Sciences that includes consulting or advisory. Jenifer M. Brown reports relationships
with Bayer AG and AstraZeneca that include consulting or advisory. Brittany N. Weber reports a
relationship with Novo Nordisk, Kiniksa Pharmaceuticals, and Horizon Therapeutics that
includes consulting or advisory. Mouaz H. Al-Mallah reports a relationship with Siemens and
GE Healthcare that includes funding grants. Mouaz H. Al-Mallah reports a relationship with GE
Healthcare, Medtrace, Jubilant, and Pfizer that includes consulting or advisory. Sharmila Dorbala
reports a relationship with Pfizer, Attralus, GE Healthcare, Siemens, and Phillips that includes
funding grants. Sharmila Dorbala reports a relationship with Novo Nordisk and Pfizer that
includes consulting or advisory. Ron Blankstein reports a relationship with Amgen Inc and

Novartis that includes funding grants. Marcelo Di Carli reports a relationship with Gilead
Sciences, Sun Pharmaceuticals, Xylocor, Intellia, Alnylam, and Amgen that includes institutional
research funding. Marcelo Di Carli reports a relationship with Sanofi, MedTrace Pharma, IBA,
Bitterroot Bio, and Valo Health that includes consulting or advisory. All other authors declare
that they have no known competing financial interests or personal relationships that could have
appeared to influence the work reported in this paper.

**Supplementary Material**
Figure S1
Figure S2
Figure S3
Figure S4
Supplementary Table 1

**References**

1.  Di Carli MF, Murthy VL. Cardiac pet/ct for the evaluation of known or suspected coronary artery disease. *Radiographics*. 2011;31:1239-1254

2.  Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac pet imaging for the detection and monitoring of coronary artery disease and microvascular health. *JACC Cardiovasc Imaging*. 2010;3:623-640

3.  Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, Dorbala S, Blankstein R, Di Carli MF. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. *Circulation*. 2015;131:19-27

4.  Zampella E, Mannarino T, D'Antonio A, Assante R, Gaudieri V, Buongiorno P, Panico M, Cantoni V, Green R, Nappi C, et al. Prediction of outcome by (82)rb pet/ct in patients with ischemia and nonobstructive coronary arteries. *J Nucl Cardiol*. 2023;30:1110-1117

5.  Jespersen L, Hvelplund A, Abildstrøm SZ, Pedersen F, Galatius S, Madsen JK, Jørgensen E, Kelbæk H, Prescott E. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. *Eur Heart J*. 2012;33:734-744

6.  Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, Boehme AK, Buxton AE, et al. Heart disease and stroke statistics-2023 update: A report from the american heart association. *Circulation*. 2023;147:e93-e621

7.  Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: Jacc state-of-the-art review. *J Am Coll Cardiol*. 2018;72:2625-2641

8.  Mehta PK, Huang J, Levit RD, Malas W, Waheed N, Bairey Merz CN. Ischemia and no obstructive coronary arteries (inoca): A narrative review. *Atherosclerosis*. 2022;363:8-21

9.  Stuijfzand WJ, Uusitalo V, Kero T, Danad I, Rijnierse MT, Saraste A, Raijmakers PG,
Lammertsma AA, Harms HJ, Heymans MW, et al. Relative flow reserve derived from
quantitative perfusion imaging may not outperform stress myocardial blood flow for
identification of hemodynamically significant coronary artery disease. *Circ Cardiovasc*
*Imaging*. 2015;8
10. Kawaguchi N, Okayama H, Kido T, Fukuyama N, Shigematsu T, Kawamura G, Hiasa G,
Kazatani Y, Inoue T, Miki H, et al. Clinical significance of corrected relative flow reserve
derived from (13)n-ammonia positron emission tomography combined with coronary
computed tomography angiography. *J Nucl Cardiol*. 2021;28:1851-1860
11. Cho SG, Park KS, Kim J, Kang SR, Song HC, Kim JH, Cho JY, Hong YJ, Jabin Z, Park HJ, et al.
Coronary flow reserve and relative flow reserve measured by n-13 ammonia pet for
characterization of coronary artery disease. *Ann Nucl Med*. 2017;31:144-152
12. Packard RRS, Votaw JR, Cooke CD, Van Train KF, Garcia EV, Maddahi J. 18f-flurpiridaz
positron emission tomography segmental and territory myocardial blood flow metrics:
Incremental value beyond perfusion for coronary artery disease categorization. *Eur*
*Heart J Cardiovasc Imaging*. 2022;23:1636-1644
13. De Bruyne B, Baudhuin T, Melin JA, Pijls NH, Sys SU, Bol A, Paulus WJ, Heyndrickx GR,
Wijns W. Coronary flow reserve calculated from pressure measurements in humans.
Validation with positron emission tomography. *Circulation*. 1994;89:1013-1022
14. Maddahi J, Lazewatsky J, Udelson JE, Berman DS, Beanlands RSB, Heller GV, Bateman
TM, Knuuti J, Orlandi C. Phase-iii clinical trial of fluorine-18 flurpiridaz positron emission
tomography for evaluation of coronary artery disease. *J Am Coll Cardiol*. 2020;76:391-
401
15. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WF, Froelicher VF, Mark DB,
Marwick TH, McCallister BD, Thompson PD, Jr., et al. Acc/aha guidelines for exercise
testing. A report of the american college of cardiology/american heart association task
force on practice guidelines (committee on exercise testing). *J Am Coll Cardiol*.
1997;30:260-311
16. Maddahi J, Bengel F, Czernin J, Crane P, Dahlbom M, Schelbert H, Sparks R, Phelps M,
Lazewatsky J. Dosimetry, biodistribution, and safety of flurpiridaz f 18 in healthy
subjects undergoing rest and exercise or pharmacological stress pet myocardial
perfusion imaging. *J Nucl Cardiol*. 2019;26:2018-2030
17. Otaki Y, Van Kriekinge SD, Wei CC, Kavanagh P, Singh A, Parekh T, Di Carli M, Maddahi J,
Sitek A, Buckley C, et al. Improved myocardial blood flow estimation with residual
activity correction and motion correction in (18)f-flurpiridaz pet myocardial perfusion
imaging. *Eur J Nucl Med Mol Imaging*. 2022;49:1881-1893
18. Lee BC, Moody JB, Poitrasson-Riviere A, Melvin AC, Weinberg RL, Corbett JR, Ficaro EP,
Murthy VL. Blood pool and tissue phase patient motion effects on (82)rubidium pet
myocardial blood flow quantification. *J Nucl Cardiol*. 2019;26:1918-1929
19. Packard RR, Huang SC, Dahlbom M, Czernin J, Maddahi J. Absolute quantitation of
myocardial blood flow in human subjects with or without myocardial ischemia using
dynamic flurpiridaz f 18 pet. *J Nucl Med*. 2014;55:1438-1444

20.  Nakazato R, Dey D, Alexanderson E, Meave A, Jimenez M, Romero E, Jacome R, Pena M,
Berman DS, Slomka PJ. Automatic alignment of myocardial perfusion pet and 64-slice
coronary ct angiography on hybrid pet/ct. *J Nucl Cardiol*. 2012;19:482-491
21.  Slomka PJ, Nishina H, Berman DS, Akincioglu C, Abidov A, Friedman JD, Hayes SW,
Germano G. Automated quantification of myocardial perfusion spect using simplified
normal limits. *J Nucl Cardiol*. 2005;12:66-77
22.  Builoff V, Lemley M, Miller RJH, Fujito H, Ramirez G, Kavanagh P, Buckley C, Di Carli M,
Berman DS, Slomka P. Subendocardial quantification enhances coronary artery disease
detection in (18)f-flurpiridaz pet. *Eur J Nucl Med Mol Imaging*. 2025
23.  Huisman MC, Higuchi T, Reder S, Nekolla SG, Poethko T, Wester HJ, Ziegler SI, Casebier
DS, Robinson SP, Schwaiger M. Initial characterization of an 18f-labeled myocardial
perfusion tracer. *J Nucl Med*. 2008;49:630-636
24.  Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ,
Rumberger JA, Ryan T, Verani MS, et al. Standardized myocardial segmentation and
nomenclature for tomographic imaging of the heart. A statement for healthcare
professionals from the cardiac imaging committee of the council on clinical cardiology of
the american heart association. *Int J Cardiovasc Imaging*. 2002;18:539-542
25.  Moody JB, Poitrasson-Riviere A, Hagio T, Buckley C, Weinberg RL, Corbett JR, Murthy VL,
Ficaro EP. Added value of myocardial blood flow using (18)f-flurpiridaz pet to diagnose
coronary artery disease: The flurpiridaz 301 trial. *J Nucl Cardiol*. 2021;28:2313-2329
26.  Gould KL, Johnson NP, Bateman TM, Beanlands RS, Bengel FM, Bober R, Camici PG,
Cerqueira MD, Chow BJW, Di Carli MF, et al. Anatomic versus physiologic assessment of
coronary artery disease. Role of coronary flow reserve, fractional flow reserve, and
positron emission tomography imaging in revascularization decision-making. *J Am Coll*
*Cardiol*. 2013;62:1639-1653
27.  Murthy VL, Bateman TM, Beanlands RS, Berman DS, Borges-Neto S, Chareonthaitawee
P, Cerqueira MD, deKemp RA, DePuey EG, Dilsizian V, et al. Clinical quantification of
myocardial blood flow using pet: Joint position paper of the snmmi cardiovascular
council and the asnc. *J Nucl Cardiol*. 2018;25:269-297
28.  Mc Ardle BA, Dowsley TF, deKemp RA, Wells GA, Beanlands RS. Does rubidium-82 pet
have superior accuracy to spect perfusion imaging for the diagnosis of obstructive
coronary disease?: A systematic review and meta-analysis. *J Am Coll Cardiol*.
2012;60:1828-1837
29.  Naya M, Murthy VL, Taqueti VR, Foster CR, Klein J, Garber M, Dorbala S, Hainer J,
Blankstein R, Resnic F, et al. Preserved coronary flow reserve effectively excludes high-
risk coronary artery disease on angiography. *J Nucl Med*. 2014;55:248-255
30.  Ziadi MC, Dekemp RA, Williams K, Guo A, Renaud JM, Chow BJ, Klein R, Ruddy TD, Aung
M, Garrard L, et al. Does quantification of myocardial flow reserve using rubidium-82
positron emission tomography facilitate detection of multivessel coronary artery
disease? *J Nucl Cardiol*. 2012;19:670-680
31.  Gupta A, Taqueti VR, van de Hoef TP, Bajaj NS, Bravo PE, Murthy VL, Osborne MT,
Seidelmann SB, Vita T, Bibbo CF, et al. Integrated noninvasive physiological assessment
of coronary circulatory function and impact on cardiovascular mortality in patients with
stable coronary artery disease. *Circulation*. 2017;136:2325-2336

32.    Cook NR. Use and misuse of the receiver operating characteristic curve in risk
595            prediction. *Circulation*. 2007;115:928-935
596    33.    Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS. Net reclassification indices
597            for evaluating risk prediction instruments: A critical review. *Epidemiology*. 2014;25:114-
598            121
599    34.    Di Carli M, Czernin J, Hoh CK, Gerbaudo VH, Brunken RC, Huang SC, Phelps ME, Schelbert
600            HR. Relation among stenosis severity, myocardial blood flow, and flow reserve in
601            patients with coronary artery disease. *Circulation*. 1995;91:1944-1951
602    35.    Beanlands RS, Muzik O, Melon P, Sutor R, Sawada S, Muller D, Bondie D, Hutchins GD,
603            Schwaiger M. Noninvasive quantification of regional myocardial flow reserve in patients
604            with coronary atherosclerosis using nitrogen-13 ammonia positron emission
605            tomography. Determination of extent of altered vascular reactivity. *J Am Coll Cardiol*.
606            1995;26:1465-1475
607    36.    Tonino PA, Fearon WF, De Bruyne B, Oldroyd KG, Leesar MA, Ver Lee PN, Maccarthy PA,
608            Van't Veer M, Pijls NH. Angiographic versus functional severity of coronary artery
609            stenoses in the fame study fractional flow reserve versus angiography in multivessel
610            evaluation. *J Am Coll Cardiol*. 2010;55:2816-2821
611    37.    Toth G, Hamilos M, Pyxaras S, Mangiacapra F, Nelis O, De Vroey F, Di Serafino L, Muller
612            O, Van Mieghem C, Wyffels E, et al. Evolving concepts of angiogram: Fractional flow
613            reserve discordances in 4000 coronary stenoses. *Eur Heart J*. 2014;35:2831-2838
614    38.    De Bruyne B, Hersbach F, Pijls NH, Bartunek J, Bech JW, Heyndrickx GR, Gould KL, Wijns
615            W. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but
616            "normal" coronary angiography. *Circulation*. 2001;104:2401-2406

659     **Tables Legends and Tables**
660
661     **Table 1. Patient characteristics**.

|                                    | N= 231          |
|------------------------------------|-----------------|
| **Demographics**                   |                 |
| Age (yrs.)                         | $61.9 \pm 9.4$  |
| Female                             | 68 (29.4%)      |
| White                              | 179 (77.5%)     |
| Black                              | 42 (18.2%)      |
| Body mass index (kg/m$^2$)         | $31.4 \pm 5.9$  |
| **Medical History**                |                 |
| Obesity                            | 131 (56.7%)     |
| Hypertension                       | 199 (86.1%)     |
| Diabetes                           | 84 (36.4%)      |
| Hyperlipidemia                     | 202 (87.4%)     |
| Tobacco use                        | 135 (58.4%)     |
| CAD                                | 145 (62.8%)     |
| Family history of CAD              | 130 (56.2%)     |
| PCI                                | 74 (32.0%)      |
| ACS                                | 11 (4.8%)       |
| Stroke                             | 13 (5.6%)       |
| CHF                                | 23 (10.0%)      |
| **Chest Pain**                     |                 |

| | | |
|---|---|---|
| Typical | 104 (45.0%) | |
| Atypical | 82 (35.5%) | |
| Nonanginal | 18 (7.8%) | |
| Asymptomatic | 27 (11.7%) | |
| **Pretest Probability of CAD** | | |
| High | 96 (41.6%) | |
| Intermediate | 108 (46.8%) | |
| Low/ very Low | 27 (11.7%) | |
| **Invasive Coronary Anatomy** | | |
| 1-vessel with $\geq$ 70% stenosis | 45 (19.5%) | |
| 2-vessel with $\geq$ 70% stenosis | 14 (6.1%) | |
| 3-vessel with $\geq$ 70% stenosis | 0 (0.0%) | |
| LM with $\geq$ 50% stenosis | 2 (0.9%) | |

662 Values are mean ± standard deviation or number (%). Pretest probability of CAD was
663 determined using the Diamond and Forrester classification.[15]
664 ACS = acute coronary syndrome; CAD = coronary artery disease; CHF = congestive heart
665 failure; LM = left main artery; PCI = percutaneous coronary intervention.
666
667
668

669 **Table 2. Per-vessel PET and ICA Results.**

| | **ALL Vessels (n = 693)** | **Nonobstructive CAD (n = 620)** | **Obstructive CAD (n = 73)** | **p-value** |
|---|---|---|---|---|
| **sMBF (ml/min/g)** | 2.22 (1.68, 2.79) | 2.32 (1.82, 2.88) | 1.38 (1.07, 1.77) | <0.0001 |
| **MFR** | 2.93 (2.23, 3.74) | 3.00 (2.35, 3.81) | 1.86 (1.56, 2.53) | <0.0001 |
| **Stress TPD $\geq$ 7%** | 129 (18.6%) | 83 (13.4%) | 46 (63.0%) | <0.0001 |
| **RFR** | 0.79 (0.66, 0.90) | 0.80 (0.70, 1.00) | 0.55 (0.43, 0.70) | <0.0001 |

670 Per-vessel values from 231 patients. Values are median (IQR) or number (%). P-values were
671 derived from clustered bootstrapping. Obstructive CAD was defined as stenosis $\geq$ 70% (or LM $\geq$
672 50%). ICA = invasive coronary angiogram; MBF = myocardial blood flow; MFR = myocardial
673 flow reserve; PET = positron emission tomography; RFR = relative flow reserve; TPD = total
674 perfusion deficit.

**Table 3. Multivariable regression models for detection of obstructive CAD in vessels with reduced stress MBF.**

| Variables | Model 1 sTPD OR | p value | Model 2 sTPD + RFR OR | p value | Model 3 sTPD + MFR OR | p value | Model 4 sTPD + MFR + RFR OR | p value |
|---|---|---|---|---|---|---|---|---|
| Age | 1.02 | 0.350 | 1.02 | 0.272 | 1.00 | 0.863 | 1.01 | 0.730 |
| Female | 1.64 | 0.292 | 1.82 | 0.214 | 1.23 | 0.645 | 1.38 | 0.476 |
| BMI | 0.98 | 0.629 | 0.99 | 0.842 | 0.98 | 0.482 | 0.99 | 0.653 |
| Stress TPD | 8.67 | <0.001 | 4.16 | <0.001 | 6.65 | <0.001 | 3.67 | <0.001 |
| RFR | | | 3.96 | <0.001 | | | 3.08 | 0.002 |
| MFR | | | | | 4.56 | <0.001 | 3.82 | <0.001 |
| sTPD x RFR[†] | | | 7.21 | 0.059 | | | 5.99 | 0.096 |
| sTPD x MFR[†] | | | | | 0.71 | 0.605 | 0.65 | 0.515 |
| MFR x RFR[†] | | | | | | | 0.89 | 0.855 |

All PET parameters in the model represent regional (per-vessel) values.

[†]Interaction terms are included for reference but were not part of the final models.

MFR = myocardial flow reserve; RFR = relative flow reserve; sTPD = stress total perfusion deficit.

**Table 4. Reclassification of obstructive CAD in vessels with reduced stress MBF**

| | Overall NRI | Obstructive CAD NRI | Nonobstructive CAD NRI | p value |
|---|---|---|---|---|
| Model 2 (sTPD + RFR) vs Model 1 (sTPD) | 0.958 (0.710, 1.206) | 0.469 (0.251, 0.686) | 0.489 (0.372,0.607) | < 0.0001 |
| Model 4 (sTPD + MFR + RFR) vs Model 3 (sTPD + MFR) | 0.927 (0.665, 1.188) | 0.438 (0.204, 0.671) | 0.489 (0.371,0.607) | < 0.0001 |

Based on 346 vessels (143 patients). Models adjusted for age, sex, and body mass index (Table 3). P-values and 95% confidence intervals for continuous net reclassification (NRI) from clustered bootstrapping. NRI for Obstructive CAD indicates the proportion of vessels with obstructive CAD that were correctly reclassified with the addition of RFR, and NRI for Nonobstructive CAD indicates the same for cases without obstructive CAD.

MFR = myocardial flow reserve; NRI = net reclassification index; RFR = relative flow reserve; sTPD = stress total perfusion deficit.

## Figure Legends and Figures

**Figure 1. Per-vessel distribution of CAD by PET flow groups.** Scatter plot of myocardial flow reserve and stress myocardial blood flow for each PET vessel territory of 693 vessels (231 patients). Dot color indicates severity of epicardial stenosis by invasive angiography in the corresponding vessel.

**Figure 2. Per-vessel obstructive CAD by abnormal stress MBF and stress TPD.** Data from 693 vessels (231 patients). Bar heights reflect group size; percentages represent the proportion of vessels with obstructive CAD (≥70% stenosis or ≥50% LM) in each group. P-values derived from chi-square tests with clustered bootstrapping. MBF = myocardial blood flow; TPD = total perfusion deficit.

**Figure 3. RFR with angiographic stenosis.** All data are from 693 vessels in 231 patients. **(A)** RFR by increasing severity of angiographic stenosis. P-value from clustered bootstrapping. **(B)** RFR distribution in obstructive versus nonobstructive vessels stratified by vascular territory. Boxes = IQR (25th–75th percentiles) with median values shown; whiskers extend to the minimum and maximum values (excluding outliers). LAD = left anterior artery; LCX = left circumflex artery; RCA = right coronary artery; RFR = relative flow reserve.

**Figure 4. Per-vessel Incremental Discriminatory Value of RFR for Identifying Obstructive CAD in Vessels with Reduced Stress MBF.** ROC curves comparing (A) sTPD alone versus sTPD and RFR, and (B) MFR alone versus MFR and RFR. Models adjusted for age, BMI, and sex. P-values and 95% confidence intervals derived from clustered bootstrapping in an analysis of 346 vessels from 143 patients. MBF = myocardial blood flow; MFR = myocardial flow reserve; RFR = relative flow reserve; ROC = receiver operating characteristic; sTPD = stress total perfusion deficit.